(0.19%) 5 318.17 points
(0.15%) 39 867 points
(0.14%) 16 819 points
(-0.93%) $79.06
(-2.76%) $2.68
(-0.48%) $2 426.80
(-0.51%) $32.26
(0.08%) $1 064.50
(0.07%) $0.921
(-0.27%) $10.67
(-0.06%) $0.787
(-0.42%) $90.30
@ $5.26
発行日: 15 2月 2024 @ 04:48
リターン: -11.25%
前回のシグナル: 2月 14 - 23:31
前回のシグナル:
リターン: 2.24 %
Live Chart Being Loaded With Signals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...
Stats | |
---|---|
本日の出来高 | 576 733 |
平均出来高 | 1.93M |
時価総額 | 425.08M |
EPS | $0 ( 2024-05-13 ) |
次の収益日 | ( $-0.250 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.19 |
ATR14 | $0.00700 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Carson William H. | Buy | 3 200 | Common Stock |
2024-04-08 | Carson William H. | Buy | 3 200 | Common Stock |
2024-02-16 | Love Douglas | Buy | 656 200 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 160 000 | Stock Option (Right to Buy) |
2024-02-16 | Dananberg Jamie | Buy | 39 000 | Common Stock |
INSIDER POWER |
---|
80.76 |
Last 94 transactions |
Buy: 9 091 580 | Sell: 849 119 |
ボリューム 相関
Annexon, Inc. 相関 - 通貨/商品
Annexon, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2023 |
収益: | $0 |
総利益: | $-3.27M (0.00 %) |
EPS: | $-1.770 |
FY | 2022 |
収益: | $0 |
総利益: | $-3.31M (0.00 %) |
EPS: | $-2.53 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-7.68 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。